Jane Street’s Metacrine, Inc. Common Stock MTCR Stock Holding History

Jane Street’s Portfolio MTCR Stock Details MTCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-88,364	Closed	-$39.6K	–	10521
2022 Q4	$39.6K	Sell	88,364 -84,964	-49%	-$35.1K	﹤0.01%	8438
2022 Q3	$84K	Buy	+173,328	New	+$85.3K	﹤0.01%	8735
2022 Q1	–	Sell	-69,003	Closed	-$47K	–	11356
2021 Q4	$47K	Buy	+69,003	New	+$123K	﹤0.01%	9561

Other funds holding MTCR

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Jane Street's MTCR Position: Q1 2023 in Review

Jane Street sold out of Metacrine, Inc. Common Stock (MTCR) in Q1 2023, closing a stake of 88,364 shares — an estimated $39.6K sold.

Jane Street first reported a position in MTCR in Q4 2021 and held it in 3 quarters. The position peaked at $84K in Q3 2022. 5 funds tracked by Wall St. Rank hold MTCR as of Q1 2023.

Jane Street reported no remaining Metacrine, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Jane Street sold 88,364 Metacrine, Inc. Common Stock shares in Q1 2023, an estimated $39.6K.
Jane Street first reported a position in Metacrine, Inc. Common Stock in Q4 2021 and held it in 3 quarters.
Jane Street's Metacrine, Inc. Common Stock position peaked at $84K in Q3 2022.
5 funds tracked by Wall St. Rank held Metacrine, Inc. Common Stock as of Q1 2023.

Based on Jane Street's 13F filing for Q1 2023, filed 16 May 2023.